Cite
HARVARD Citation
Schobel, S. et al. (n.d.). J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington's disease (hd). Journal of neurology, neurosurgery and psychiatry. p. A98. [Online].